AI Summary & Key Takeaways
AI InsightPatients should be informed about the importance and continuity of the treatment and follow-up procedures because of the possiblity of the relapses and treatment modality modifications.
📌 3 Key Takeaways
Abstract
Graves is an autoimmune disease which is the most frequently seen etiology of thyrotoxicosis. In this study demographic features, laboratory findings, treatment modalities and results of the treatments in 78 Graves' disease outpatients (61 female, 17 male) treated with propyrthiouracil were evaluated retrospectively. Symptoms and signs on admission were tremor 57.8%, weakness 47.3%, heat intolerance 47.3%, weight loss 46%, easy fatiquability 22.3% and ophtalmopathy of different degrees 32.5%. After a treatment period of 16.8 ± 9.6 months with propylthiouracil, among 59 patients who were followed up without medication, relapses were seen in 30.5% after a mean period of9.5 ± 4.7 months. Radioactive iodine treatment was given to 55.5% and surgery was performed in 44.4% of the patients who relapsed.Results of our study indicated that antithyroid drug regimen is the first treatment of choice in Graves disease. Treatment period should last at least 1 year after patients became euthyroid. In cases in whom relapses occu-red radioactive iodine treatment and surgery should be the alternative treatment regimens. Patients should be informed about the importance and continuity of the treatment and follow-up procedures because of the possiblity of the relapses and treatment modality modifications.
Özet
Graves otoimmun bir hastalik olup tirotoksikoz yapan nedenler içerisinde en sik görülenidir. Bu çalışmada Graves tanısı alarak propiltiyourasil tedavisi uygulanan 61'i kadin 17'si erkek toplam 78 poliklinik hastamizin demografik özelliklerinin, laboratuvar bulgularının, uygulanan tedavi modalitelerinin ve sonuçlarının retrospektif olarak değerlendirilmesi amaçlanmıştır. Başvuru sirasında hastaların %57.8'inde tremor, %47.3'unde halsizlik, %47.3'unde sıcak intoleransi, %46'sinda kilo kaybi, %22.3'unde çabuk yorulma yakınmasi ve %32.5'inde çesitli derecelerde oftalmopati bulgusu mevcuttu. Ortalama 16.8 ± 9.6 ay propiltiyourasil tedavisini takiben ilaçsiz izleme alinan 59 hastanin %30.5'inde ortalama 9.5 ± 4.7 ay sonra nüks görüldü.Nüks görülenlerin %55.5'inde radyoaktif iyot tedavisi, %44.4'unde subtotal tiroidektomi uygulandi. Sonuç olarak, Graves'li olgularda ilk tedavi alternatifi antitiroid ilaç tedavisidir. Otiroid statusa getirilen hastalarda idame dozda antitiroid tedavi en az 1 yil daha sürdürülmelidir. Nüks görülen olgularda radyoaktif iyot ve cerrahi diger tedavi alternatifleridir. Ayrica olasi nüksler ve tedavi modalite değişiklikleri nedeniyle hastalar tedavi ve takiplerin sürekliliği konusunda bilinçlendirilmelidir.